Early Growth Response-1 Suppresses Epidermal Growth Factor Receptor-Mediated Airway Hyperresponsiveness and Lung Remodeling in Mice

Transforming growth factor (TGF)-alpha and its receptor, the epidermal growth factor receptor, are induced after lung injury and are associated with remodeling in chronic pulmonary diseases, such as pulmonary fibrosis and asthma. Expression of TGF-alpha in the lungs of adult mice causes fibrosis, pl...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory cell and molecular biology Vol. 41; no. 4; pp. 415 - 425
Main Authors Kramer, Elizabeth L, Mushaben, Elizabeth M, Pastura, Patricia A, Acciani, Thomas H, Deutsch, Gail H, Khurana Hershey, Gurjit K, Korfhagen, Thomas R, Hardie, William D, Whitsett, Jeffrey A, Le Cras, Timothy D
Format Journal Article
LanguageEnglish
Published United States Am Thoracic Soc 01.10.2009
American Thoracic Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Transforming growth factor (TGF)-alpha and its receptor, the epidermal growth factor receptor, are induced after lung injury and are associated with remodeling in chronic pulmonary diseases, such as pulmonary fibrosis and asthma. Expression of TGF-alpha in the lungs of adult mice causes fibrosis, pleural thickening, and pulmonary hypertension, in addition to increased expression of a transcription factor, early growth response-1 (Egr-1). Egr-1 was increased in airway smooth muscle (ASM) and the vascular adventitia in the lungs of mice conditionally expressing TGF-alpha in airway epithelium (Clara cell secretory protein-rtTA(+/-)/[tetO](7)-TGF-alpha(+/-)). The goal of this study was to determine the role of Egr-1 in TGF-alpha-induced lung disease. To accomplish this, TGF-alpha-transgenic mice were crossed to Egr-1 knockout (Egr-1(ko/ko)) mice. The lack of Egr-1 markedly increased the severity of TGF-alpha-induced pulmonary disease, dramatically enhancing airway muscularization, increasing pulmonary fibrosis, and causing greater airway hyperresponsiveness to methacholine. Smooth muscle hyperplasia, not hypertrophy, caused the ASM thickening in the absence of Egr-1. No detectable increases in pulmonary inflammation were found. In addition to the airway remodeling disease, vascular remodeling and pulmonary hypertension were also more severe in Egr-1(ko/ko) mice. Thus, Egr-1 acts to suppress epidermal growth factor receptor-mediated airway and vascular muscularization, fibrosis, and airway hyperresponsiveness in the absence of inflammation. This provides a unique model to study the processes causing pulmonary fibrosis and ASM thickening without the complicating effects of inflammation.
Bibliography:Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
Correspondence and requests for reprints should be addressed to Tim Le Cras, Ph.D., Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229. E-mail: tim.lecras@cchmc.org
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
This work was supported in part by National Institutes of Health grants HL72894 (T.D.L.C.), HL58795 (T.R.K.), HL86598 (W.D.H.), HL90156 (J.A.W.), and HL61646 (J.A.W.), and by American Heart Association grant 740069N (T.D.L.C.).
Originally Published in Press as DOI: 10.1165/rcmb.2008-0470OC on February 2, 2009
ISSN:1044-1549
1535-4989
DOI:10.1165/rcmb.2008-0470OC